Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Nike stock analysis & discuss the risks and upside potential of NKE stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
03 Apr 2026, 22:26 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for Friends! In this video, I'm going to do a Nike stock analysis & discuss the risks and upside potential of NKE stock
Source overview

AI-generated source summary

The analysis focuses on Nike's (NKE) stock, noting its significant decline over the past five years and its current status as potentially undervalued. Despite recent earnings that beat expectations, the company faces challenges, particularly in the Chinese market where sales are shrinking. The stock's forward P/E ratio is trading at a multiple of 25, which is considered high given the projected lower earnings growth in the coming years. The analyst suggests that while Nike offers a dividend yield, there are more attractive investment opportunities available in the market with better growth prospects and valuation multiples.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail